This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
Development Pipeline
Today, our research efforts are dedicated to advancing a diverse pipeline of innovative therapies for solid tumors and blood-related cancers.
Learn about our development programs by selecting an agent below or click to explore our interactive pipeline.
Brentuximab vedotin
an antibody–drug conjugate directed to CD30 being investigated in certain lymphomas and solid tumors
Tucatinib
a highly selective small molecule tyrosine kinase inhibitor being investigated in multiple HER2-overexpressed/amplified and HER2-mutated cancers
SGN-35T
an investigational CD30-directed, next generation antibody-drug conjugate with novel tripeptide linker
SGN-CEACAM5C
an investigational topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5
SGN-BB228
an investigational costimulatory bispecific molecule composed of a CD228-directed antibody and 4-1BB-directed Anticalin® proteins
SGN-EGFRd2
an investigational bispecific gamma delta (γδ)-T cell engager directed to EGFR